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LETTERS TO THE EDITOR
ERCC2/XPD
Polymorphisms and
Lung Cancer Risk
To the Editor:
I read with interest, the recently
published meta-analysis by Zhan et al.,1
involving 22 case-control studies of the
excision repair cross-complimenting ro-
dent repair deficiency, complementation
group 2 (ERCC2/XPD) polymorphisms
and lung cancer risk. Nevertheless,
there is one error in the article that
diminishes the findings and conclu-
sions considerably.
The authors cite in Table 1 that
our study, the largest among the 22 an-
alyzed, comprised Asian (Chinese) eth-
nicity.2 Nevertheless, although the first
author of this article from my research
group is a Chinese national, the popula-
tion was 100% white from the New
England region of the United States.
Hence, the results presented in Figures 1
and 2 are incorrect and should be recal-
culated. Moreover, the interpretation of
results and conclusions should be also
revised accordingly.
David C. Christiani, MD, MPH
Department of Medicine
Massachusetts General Hospital/Harvard
Medical School
Harvard School of Public Health
Boston, Massachusetts
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In Response:
Because of our carelessness, we
made a mistake about the ethnicity (coun-
try of origin) of the study by Zhou et al.1
The population in the study by Zhou et al.1
was Caucasian from the United states;
however, in our study,2 it was stated as
Asian (Chinese). Hence, we had to recal-
culate the meta-analysis results according
to the ethnicity subgroup analysis.
For the Xeroderma Pigmentosum
group D (XPD) Lys751Gln genotype,
when stratified by ethnicity, significantly
increased risks were found among Cauca-
sians for both the homozygote CC versus
AA (odds ratio [OR]  1.30, 95% confi-
dence interval [CI]  1.15–1.48; p 
0.923 for heterogeneity) and the C allele
carriers versus AA (OR  1.21, 95%
CI  1.16–1.58; p  0.358 for heteroge-
neity). Among Asians, no significant as-
sociation was found in homozygote CC
versus AA (OR  1.07; 95% CI  0.67–
1.72; p  0.194 for heterogeneity) or for
the C allele carriers versus AA (OR 
1.14; 95% CI 0.73–1.62; p 0.278 for
heterogeneity) (Figure 1).
For the XPD Asp312Asn geno-
type, when stratified by ethnicity, sig-
nificantly increased risks were found
among Caucasians for both the ho-
mozygote AA versus GG (OR  1.20,
95% CI  1.05–1.38; p  0.460 for
heterogeneity) and the A allele carriers
versus GG (OR  1.34, 95% CI 
1.11–1.74; p  0.374 for heterogene-
ity). Among Asians, significantly in-
creased risks was also found with ho-
mozygote AA versus GG (OR  5.07;
95% CI  2.09–12.34; p  0.049 for
heterogeneity) or the A allele carriers
versus GG (OR  4.54; 95% CI 
1.83–8.52; p  0.374 for heterogene-
ity) (Figure 2).
When stratified according to ethnic-
ity, different results were found between
Asians and Caucasians for the XPD
Lys751Gln genotype but not Asp312Asn
genotype. For the XPD Lys751Gln geno-
type, significantly increased risks were
identified among Caucasians for both the
homozygote CC versus AA and the C
allele carriers versus AA. Among Asians,
however, no significant association was
found in homozygote CC versus AA or
the C allele carriers versus AA, which was
consistent with our previous study.2 For
the Asp312Asn genotype, the increased
risks were apparent with not only Cauca-
sians but Asians for both the homozygote
CC versus AA and the C allele carriers
versus AA, which was consistent with the
results of the meta-analysis study by
Zhang et al.3 These findings indicated that
polymorphisms of XPD may be important
in regard to specific ethnicity of patients
with lung cancer and that XPD Lys751Gln
may differentially affect individuals of
different ethnic genetic backgrounds for
risk of lung cancer. Population stratifica-
tion is an area of concern in any complex
disease association study as it can con-
found the linkage results between a mo-
lecular marker and phenotype.4 The ob-
served ethnic differences may also be a
result of chance because studies with
small sample size are likely to be insuffi-
ciently powered to detect a slight effect. In
addition, the heterogeneity test among
Asians studies for XPD Asp312Asn geno-
type was significant. Considering the lim-
ited studies and population numbers of
Asians studies in this meta-analysis, our
results among Asians should be inter-
preted with caution. Hence, large case-
control studies on the association between
the XPD gene polymorphism and lung
cancer risk among Asians should be con-
ducted in the future.
In summary, this meta-analysis
suggested that the XPD Lys751Gln and
Asp312Asn gene polymorphisms were
associated with lung cancer risk; the C
allele of XPD Lys751Gln genotype was
an increased risk factor for developing
lung cancer among Caucasians, and the
A allele of the XPD 312 genotype was
also an increased risk factor for devel-
oping lung cancer among Asians and
Caucasians.
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